"“Putting our money where our mouth is!
Lenstec’s Director of Clinical Research, Blake Harris, is one of the many elated patients who chose to have the ClearView™ 3 multifocal IOL implanted. He was the study manager for the FDA study for the lens, so knows all the ins and outs of its performance. That lead him to Whitsett Vision Group (Jeff Whitsett, MD), who was the lead enroller in the FDA study.
Clinically, Blake has visions of 20/20 for distance, 20/20 for intermediate and J1 for near! He’s completely spectacle free so goodbye reading glasses! Above all, Blake reports he is free of any visual disturbance! The lens has literally changed his life!
Lenstec’s Director of Clinical Research, Blake Harris, is one of the many elated patients who chose to have the ClearView™ 3 multifocal IOL implanted. He was the study manager for the FDA study for the lens, so knows all the ins and outs of its performance. That lead him to Whitsett Vision Group (Jeff Whitsett, MD), who was the lead enroller in the FDA study.
Clinically, Blake has visions of 20/20 for distance, 20/20 for intermediate and J1 for near! He’s completely spectacle free so goodbye reading glasses! Above all, Blake reports he is free of any visual disturbance! The lens has literally changed his life!